SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Costantino who wrote (1134)7/18/1997 10:25:00 PM
From: Brad C. Dunlap   of 1762
 
Hi Rick, I have know idea how Idec will hold in the short run but I do think it is important to distinguish between next weeks FDA panel meeting and the actual FDA approval. As we all know the FDA in almost all cases goes along with the FDA panel's decision and if the stock were to sell off on good news from the panel I believe it would be short in duration as buyers would surface as the actual FDA approval approaches. There is no telling when the actual FDA approval would happen assuming a successful panel meeting but under the Clinton oncology initiative, supposedly all cancer applications to the FDA are to be approved/disapproved within six months of the filing date. Since Idec/Genentech filed the end of Feb and publically announced the filing the first part of March, we might anticipate the FDA approval sometime the end of August or the beginning of September.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News